5.165
price up icon1.08%   0.065
 
loading
Verastem Inc stock is traded at $5.165, with a volume of 796.04K. It is up +1.08% in the last 24 hours and up +4.56% over the past month. Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
See More
Previous Close:
$5.10
Open:
$5.1
24h Volume:
796.04K
Relative Volume:
0.37
Market Cap:
$283.54M
Revenue:
$3.64M
Net Income/Loss:
$-87.37M
P/E Ratio:
-1.2567
EPS:
-4.11
Net Cash Flow:
$-86.46M
1W Performance:
+5.42%
1M Performance:
+4.56%
6M Performance:
-6.61%
1Y Performance:
+50.73%
1-Day Range:
Value
$4.86
$5.165
1-Week Range:
Value
$4.81
$5.57
52-Week Range:
Value
$2.10
$9.10

Verastem Inc Stock (VSTM) Company Profile

Name
Name
Verastem Inc
Name
Phone
(781) 292-4200
Name
Address
117 KENDRICK STREET, NEEDHAM, MA
Name
Employee
78
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
VSTM's Discussions on Twitter

Compare VSTM with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
VSTM
Verastem Inc
5.16 272.55M 3.64M -87.37M -86.46M -4.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.96 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
556.83 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.82 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
574.62 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.65 27.29B 3.81B -644.79M -669.77M -6.24

Verastem Inc Stock (VSTM) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-10-25 Initiated Jefferies Buy
Mar-24-25 Reiterated H.C. Wainwright Buy
Dec-31-24 Reiterated BTIG Research Buy
Sep-30-24 Initiated Guggenheim Buy
Nov-21-23 Resumed BTIG Research Buy
Sep-27-23 Initiated B. Riley Securities Buy
Jun-15-23 Upgrade Mizuho Neutral → Buy
Sep-07-22 Resumed Alliance Global Partners Buy
Apr-29-22 Resumed Cantor Fitzgerald Overweight
Apr-14-22 Initiated RBC Capital Mkts Outperform
Mar-09-22 Initiated Truist Buy
Jul-01-21 Initiated Alliance Global Partners Buy
May-24-21 Upgrade BTIG Research Neutral → Buy
Jun-20-19 Downgrade BTIG Research Buy → Neutral
May-10-19 Downgrade Raymond James Outperform → Mkt Perform
Jul-13-18 Initiated BTIG Research Buy
May-02-18 Initiated Seaport Global Securities Buy
Mar-08-18 Initiated B. Riley FBR, Inc. Buy
Sep-07-17 Reiterated H.C. Wainwright Buy
Apr-13-17 Initiated Oppenheimer Outperform
Mar-24-17 Reiterated H.C. Wainwright Buy
Sep-29-15 Downgrade Cantor Fitzgerald Buy → Hold
Sep-29-15 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-29-15 Downgrade Jefferies Buy → Hold
Sep-29-15 Downgrade Raymond James Strong Buy → Outperform
Sep-28-15 Downgrade Mizuho Buy → Neutral
Sep-28-15 Downgrade ROTH Capital Buy → Neutral
Sep-09-15 Initiated Raymond James Strong Buy
May-12-15 Reiterated UBS Buy
Apr-08-15 Initiated H.C. Wainwright Buy
Jan-23-15 Reiterated ROTH Capital Buy
Jul-08-14 Resumed Oppenheimer Perform
Feb-11-14 Initiated Mizuho Buy
View All

Verastem Inc Stock (VSTM) Latest News

pulisher
12:46 PM

(VSTM) Proactive Strategies - news.stocktradersdaily.com

12:46 PM
pulisher
11:05 AM

What analysts say about Verastem Inc. stockFree Daily Trading Room Entry - Autocar Professional

11:05 AM
pulisher
08:03 AM

Is Verastem Inc. a good long term investmentConsistent triple-digit returns - jammulinksnews.com

08:03 AM
pulisher
Jul 21, 2025

What drives Verastem Inc. stock priceBreakthrough stock performance - Autocar Professional

Jul 21, 2025
pulisher
Jul 20, 2025

Verastem Inc. Stock Analysis and ForecastFree Market Dynamics Reports - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 18, 2025

Verastem’s Promising KRAS G12D Inhibitor Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 16, 2025

Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM) - Seeking Alpha

Jul 16, 2025
pulisher
Jul 16, 2025

Why Verastem Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Verastem Inc. stock price move sharplyEntry Level Low Risk Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Verastem Inc. stock performs during market volatilityFast Moving Stock Alerts - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Avutometinib-Defactinib: A New Standard in Precision Oncology? - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial - Yahoo Finance

Jul 14, 2025
pulisher
Jul 11, 2025

Verastem Oncology's Breakthrough in LGSOC: A New Standard of Care with Substantial Upside Potential - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem’s cancer drug shows 31% response rate in ovarian cancer trial By Investing.com - Investing.com Canada

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem stock rises after LGSOC treatment data published in medical journal - Investing.com

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem stock rises after LGSOC treatment data published in medical journal By Investing.com - Investing.com South Africa

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology - Yahoo Finance

Jul 11, 2025
pulisher
Jul 10, 2025

KRAS Inhibitors Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Target Population, Revenue, Statistics, MOA, ROA and Companies DelveInsight - Barchart.com

Jul 10, 2025
pulisher
Jul 08, 2025

Verastem Oncology's Talent Incentives: Balancing Equity Dilution and Growth - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Verastem Oncology announces inducement grants under Nasdaq listing rule - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Verastem Oncology Awards 45,000 Share Options at $4.29 Each to Expand Cancer Drug Development Team - Stock Titan

Jul 08, 2025
pulisher
Jul 04, 2025

Verastem’s Phase 3 Study on Avutometinib and Defactinib: A Potential Game-Changer for Ovarian Cancer Treatment - TipRanks

Jul 04, 2025
pulisher
Jul 02, 2025

Verastem’s Promising Phase 3 Study on Recurrent Ovarian Cancer - TipRanks

Jul 02, 2025
pulisher
Jul 01, 2025

How the (VSTM) price action is used to our Advantage - news.stocktradersdaily.com

Jul 01, 2025
pulisher
Jun 30, 2025

Verastem’s Promising Phase 3 Study on Avutometinib and Defactinib in Ovarian Cancer - TipRanks

Jun 30, 2025
pulisher
Jun 28, 2025

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Jun 28, 2025
pulisher
Jun 26, 2025

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers - Seeking Alpha

Jun 26, 2025
pulisher
Jun 25, 2025

Verastem (VSTM) Target Price Lowered by RBC Capital | VSTM Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

RBC Capital Adjusts Target Price for Verastem (VSTM) to $12 | VSTM Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors - BioSpace

Jun 25, 2025
pulisher
Jun 24, 2025

Verastem Executives Sell Shares to Meet Tax Obligations - TradingView

Jun 24, 2025
pulisher
Jun 20, 2025

Verastem CEO Paterson sells $1.8k in shares By Investing.com - Investing.com Canada

Jun 20, 2025
pulisher
Jun 13, 2025

Verastem’s SWOT analysis: biotech stock poised for growth amid challenges By Investing.com - Investing.com South Africa

Jun 13, 2025
pulisher
Jun 13, 2025

Verastem’s SWOT analysis: biotech stock poised for growth amid challenges - Investing.com

Jun 13, 2025
pulisher
Jun 10, 2025

(VSTM) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Jun 10, 2025
pulisher
Jun 06, 2025

Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish - MSN

Jun 06, 2025
pulisher
Jun 03, 2025

ASCO 2025: Verastem has positive cancer data but stock sags - BioWorld MedTech

Jun 03, 2025
pulisher
Jun 03, 2025

Cantor Fitzgerald reiterates overweight rating on Verastem stock By Investing.com - Investing.com Nigeria

Jun 03, 2025
pulisher
Jun 02, 2025

Transcript : Verastem, Inc.Special Call - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

What's Going On With Verastem Oncology Stock On Monday? - Benzinga

Jun 02, 2025

Verastem Inc Stock (VSTM) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$21.81
price up icon 0.53%
$35.87
price up icon 0.53%
$103.52
price up icon 0.74%
$26.48
price up icon 0.44%
$109.96
price up icon 0.27%
biotechnology ONC
$294.56
price up icon 0.85%
Cap:     |  Volume (24h):